Altered expression and functional responses to cardiac ␤ 3 -adrenergic receptors (ARs) may contribute to progressive cardiac dysfunction in heart failure (CHF). We compared myocyte ␤ 3 -AR mRNA and protein levels and myocyte contractile, [Ca 2ϩ ] i transient, and Ca 2ϩ current (I Ca,L ) responses to BRL-37344 (BRL, 10 Ϫ8 mol/L), a selective ␤ 3 -AR agonist, in 9 instrumented dogs before and after pacing-induced CHF. Myocytes were isolated from left ventricular myocardium biopsy tissues. Using reverse transcription-polymerase chain reaction, we detected ␤ 3 -AR mRNA from myocyte total RNA in each animal. Using a cloned canine ␤ 3 -AR cDNA probe and myocyte poly A ϩ RNA, we detected a single band about 3.4 kb in normal and CHF myocytes. ␤ 3 -AR protein was detected by Western blot. ␤ 3 -AR mRNA and protein levels were significantly greater in CHF myocytes than in normal myocytes. Importantly, these changes were associated with enhanced ␤ 3 -AR-mediated negative modulation on myocyte contractile response and [Ca 2ϩ ] i regulation. Compared with normal myocytes, CHF myocytes had much greater decreases in the velocity of shortening and relengthening with BRL accompanied by larger reductions in the peak systolic [Ca 2ϩ ] i transient and I Ca,L . These responses were not modified by pretreating myocytes with metoprolol (a ␤ 1 -AR antagonist) or nadolol (a ␤ 1 -and ␤ 2 -AR antagonist), but were nearly prevented by bupranolol or L-748,337 (␤ 3 -AR antagonists). We conclude that in dogs with pacing-induced CHF, ␤ 3 -AR gene expression and protein levels are upregulated, and the functional response to ␤ 3 -AR stimulation is increased. This may contribute to progression of cardiac dysfunction in CHF. (Circ Res. 2001; 89:599-606.)
B eta-adrenergic receptors (ARs) are integral membrane proteins belonging to the class of G protein-coupled receptors. [1] [2] [3] It has been well-established that cardiac ␤ 1 -and ␤ 2 -ARs mediate the catecholamine-induced increase in force and frequency of cardiac contractions, thereby providing a mechanism for myocardial contractile reserve. Congestive heart failure (CHF) is associated with a progressive activation of the sympathetic nervous system (SNS), but a diminished positive inotropic response to ␤-AR stimulation, in part because of a selective downregulation of ␤ 1 -ARs and an upregulated inhibitory G protein (G i ). 1 However, recent observations in human hearts indicate a more complex ␤-AR-mediated regulation of myocardial inotropism by catecholamines.
Evidence has been provided that ␤ 3 -ARs may also modulate cardiac function. 4 -7 However, unlike ␤ 1 -or ␤ 2 -ARs, the function of ␤ 3 -ARs is to inhibit cardiac contraction. Gauthier and colleagues 5 first demonstrated that ␤ 3 -ARs, initially found to be widely expressed in adipose, 8 are also expressed in the human heart, and that stimulation of ␤ 3 -ARs with a preferential agonist, BRL-37344 (BRL), caused dosedependent negative inotropic effects. This ␤ 3 -AR-mediated negative inotropic effect is not linked to stimulatory G proteins but is coupled to G i . 5, 6 Although the precise physiological and pathophysiologic roles of ␤ 3 -AR remain uncertain, recent observations suggest that in the normal heart, ␤ 3 -AR participates in nitric oxide (NO)-mediated negative feedback control over contractility within the SNS because stimulation of ␤ 3 -ARs with BRL resulted in a negative inotropic effect in human donor hearts through NO signaling, 9 and ␤ 3 -AR deficiency blocked NOdependent inhibition of myocardial contractility in transgenic mice. 10 In failing human hearts, ␤ 3 -AR abundance was increased, and the balance between opposing inotropic influences of ␤ 1 -ARs and ␤ 3 -ARs was significantly altered, providing a potential mechanism for progressive deterioration in cardiac function. 4 The role of ␤ 3 -ARs could be more clearly elucidated using defined animal models of CHF. Past studies of cardiac ␤ 3 -AR function and gene expression performed in normal animals have yielded conflicting findings [5] [6] [7] [11] [12] [13] because of the confounding effects of anesthesia, open-chest surgery, tissue preparation, loading conditions, species differences, and use of multicellular preparations. The molecular expression, the functional effect of ␤ 3 -ARs on single-cell mechanics, and the dynamics of the cytosolic [Ca 2ϩ ] i have not been previously assessed in an integrated fashion in normal cardiomyocytes and those from animals with varying degrees of CHF. Virtually no previous studies have specifically examined ␤ 3 -AR-induced changes in calcium current (I Ca,L ). 14 Furthermore, the CHF-induced alterations of functional effects and gene expression of cardiac ␤ 3 -AR have not been determined in nonhuman species. This has important pharmacological and clinical implications because the vast majority of therapeutic drugs are evaluated in animal models.
Accordingly, we tested the hypothesis that in CHF, ␤ 3 -AR expression is increased. This augmentation is proposed to exacerbate the dysfunctional [Ca 2ϩ ] i regulation, enhance inhibition of cardiac contraction and relaxation, and lead to worsening cardiac failure.
To obviate the limitations in previous studies, we used a more clinically relevant canine CHF model 1, 3, 13 and conducted studies in cardiomyocytes freshly isolated from left ventricular (LV) myocardium obtained by biopsy from the same animals before and after CHF. 13 We compared alterations in normal and CHF myocyte steady-state ␤ 3 -AR mRNA and protein levels, changes in normal and CHF myocyte contractile performance, [Ca 2ϩ ] i transient ([Ca 2ϩ ] iT ), and I Ca,L responses to ␤ 3 -AR stimulation.
The present findings extend our knowledge regarding the cellular and molecular determinants of an enhanced ␤ 3 -ARmediated negative inotropic effect in CHF, provide valuable new insight into the mechanism of the progression of functional impairment in CHF, and may assist in specifically targeting therapy for CHF.
Materials and Methods
Using techniques well-established in our laboratory, 13 myocytes were isolated from LV myocardium obtained from 9 instrumented dogs before and after pacing-induced CHF.
Canine ␤ 3 -AR Gene Sequencing, Myocyte ␤ 3 -AR mRNA, and Protein Levels

Sequencing of Canine ␤ 3 -AR Gene
A 525-bp DNA fragment corresponding to canine ␤ 3 -AR coding region (bases 115 to 640) was produced by polymerase chain reaction (PCR) with primers: sense, 5Ј-GCTCCGTGGCCT-CACGGGAA-3Ј, and antisense, 5Ј-CTTGCTCATGATG-GGCGC-3Ј and cloned into PCR 2.1 (Invitrogen). DNA sequencing of the recombinant plasmid was performed with T7 and M13 specific primers.
Myocyte Expression of ␤ 3 -AR mRNA
Cardiomyocyte total RNA was extracted by RNAqueous phenol-free total RNA isolation kit (Ambion) and treated with RNase-free DNase I (GIBCO BRL). The reverse transcription (RT) reaction was performed with RETROscript first-strand synthesis kit (Ambion) using the antisense primer. The cDNA produced was amplified by PCR.
Northern Blot
Poly A ϩ RNA was isolated from total RNA using poly (A) Pure mRNA isolation kit (Ambion). ␤ 3 -AR mRNA was analyzed by using Northern Max (Ambion). The 525-bp cDNA probe of canine ␤ 3 -AR was labeled by random priming with [␣-32 P]dCTP (3000 Ci/mmol, DuPont) with the use of DECAprime II (Ambion). Hybridization was performed at 42°C overnight in the presence of 500 g/mL salmon sperm DNA. For standardization, the same blot was reprobed with a GAPDH probe.
Western Blot
LV myocytes were briefly washed with prechilled PBS before the addition of a protein-extraction reagent (Pierce) with proteinase inhibitor cocktail. Cell lysate (50 g) was blotted to a PVDF membrane. The membrane was incubated with a polyclonal IgG to ␤ 3 -AR (1:1500 dilution, Alpha Diagnostic) at 4°C overnight. Following washes, the membrane was incubated with horseradish peroxidase-conjugated anti-rabbit IgG (1:3000 dilution, Sigma). For normalization, the same blot was reprobed with IgG polyclonal antibody to actin at 1:2500 dilution (Santa Cruz Biotechnology Inc).
Functional Studies
Effects of ␤ 3 -AR on Myocyte Contractile Response and [Ca 2؉ ] i Regulation
BRL, a frequently studied, selective ␤ 3 -AR agonist, causes potent depressions of myocardial contraction in humans, dogs, and rats 15 and altered cardiac contractile response in failing human hearts. 4 The dosing protocol of BRL (10 Ϫ8 mol/L) used in this study was identified from our initial dose-response study.
Measurement of Contractile Response
A dose-response study was performed in 5 animals. Briefly, myocyte contractions were elicited by a field stimulation. 13 After stabilization, steady-state data were recorded. Myocytes were randomly exposed to BRL (10 Ϫ10 to 10 Ϫ7 mol/L), and data were acquired after 3 to 5 minutes of drug exposure and 5 to 15 minutes after drug washout. We found that BRL of 10 Ϫ8 mol/L was well-tolerated by both normal and CHF myocytes and caused nearly maximum reduction in the percent shortening (ie, systolic amplitude [SA]) ( Figure 3A and Table) . Higher concentrations of BRL were frequently associated with arrhythmias in CHF myocytes. Thus, the effects of BRL 10 Ϫ8 mol/L were assessed in the following series of experiments.
Myocyte contractile response to BRL 10 Ϫ8 mol/L was examined in 9 animals. In 3 subgroups, BRL-mediated actions were determined after pretreatment of myocytes with (1) metoprolol (10 Ϫ6 mol/L, a ␤ 1 -AR antagonist), nadolol (10 Ϫ5 mol/L, a ␤ 1 -and ␤ 2 -AR antagonist), and bupranolol (10 Ϫ6 mol/L, a nonselective ␤ 3 -AR antagonist) in 6 animals, or L-748,337 (10 Ϫ7 mol/L, a selective ␤ 3 -AR antagonist) in 2 animals for 5 minutes in random order, (2) with NO synthase inhibitor N G nitro-L-arginine methyl ester (L-NAME) (10 Ϫ4 mol/L, 30 minutes), and (3) with G i inhibitor pertussis toxin (PTX) (2 g/mL, 36°C, 5 hours) inactivated cardiac G i in 5 animals. 2, 16 To determine the cellular basis for the ␤ 3 -AR-mediated contractile action, the following experiments were performed in two additional series-studies in 9 animals.
Simultaneous Measurement of Calcium Transient and Contractile Response
In the second series of experiments, [Ca 2ϩ ] i transient ([Ca 2ϩ ] iT ) and contraction responses in a single myocyte were simultaneously measured as described previously. 17 After stabilization, the BRL protocol was repeated. When myocytes were loaded with indo-1-AM, compartmentalization of the indicator may have occurred in the mitochondria, thus the absolute value of [Ca 2ϩ ] i was not used. As described in our past report, 17 the ratio of the emitted fluorescence (410/490) was used to represent the relative changes in peak intracellular [Ca 2ϩ ] i before and after BRL. 17 The actual fluorescence ratios were also calibrated as described by O'Neill et al. 18 
Measurement of Calcium Current Response
In the third series of experiments, the I Ca,L response to BRL (10 Ϫ8 mol/L) was measured by whole-cell patch-clamp technique. 2 After baseline I Ca,L , data were obtained during the 0 to 10 minutes of BRL superfusion and during the period of washout of BRL.
Statistical Analysis
Data were summarized as meanϮSD. Multiple comparisons were performed by analysis of variance. When a significant overall effect was present, intergroup comparisons were performed by using a Bonferroni correction for multiple comparisons. Two-tailed, paired Student's t tests were used to evaluate mean differences in hemodynamic parameters and cell-functional response indexes before and after CHF. Myocyte functional data were averaged from the number of myocytes studied from each animal. Then myocyte functional data were analyzed by using the mean measurements obtained for each dog before and after CHF. Significance was established as PϽ0.05.
Drugs
Bupranolol HCL was a gift from Schwarz Pharma (Monheim, Germany). BRL-37344 was obtained from Tocris. L-748,337 was a gift from Merck Research Laboratories (Rahway, NJ). Nadolol, L-NAME, and PTX were obtained from Sigma Chemical Co.
Results
Canine ␤ 3 -AR Gene, ␤ 3 -AR mRNA, and Protein Levels in Normal and CHF Myocytes
As presented in Figure 1 , a fragment of canine ␤ 3 -AR DNA with a predicated size of 525 bp was produced by PCR. The sequence of the fragment was 100% homologous to the corresponding region of the published canine ␤ 3 -AR cDNA (GenBank No. U92468). By RT-PCR, the same size of ␤ 3 -AR mRNA was detected identically in both normal and CHF groups, with the predicated size of 525 bp. Figure 2A shows that in normal myocytes, a single band of ␤ 3 -AR mRNA, about 3.4 kb, was present only in the poly A ϩ RNA samples. The same size of ␤ 3 -AR mRNA was detected from each animal before and after CHF. Compared with normal myocytes, CHF myocytes had a significantly higher (73%) signal ratio of ␤ 3 -AR mRNA to GAPDH (2.20Ϯ0.2 versus 3.8Ϯ0.3) (PϽ0.05) ( Figure 2B ). With Western blot analysis, a single band of ␤ 3 -AR protein, about 65 to 70 kDa, was detected. Compared with normal myocytes, in CHF myocytes, the signal ratio of ␤ 3 -AR protein to actin was increased to approximately 247% (1.72Ϯ0.9 versus 4.25Ϯ2.7) (PϽ0.05), indicating increased ␤ 3 -AR protein levels in CHF ( Figure 2C ).
Effect of BRL on Contractile, [Ca 2؉ ] iT , and I Ca,L Responses in Normal and CHF Myocytes
Consistent with our previous reports, significant myocyte dysfunction was evident in CHF myocytes. 13 CHF myocytes were enlarged, and the length-width ratio was greater (58.1Ϯ6.3%) (PϽ0.05) than normal cells. The SA, the velocity of shortening (dL/dt max ) and relengthening (dR/dt max ), peak systolic [Ca 2ϩ ] iT , and I Ca,L in CHF myocytes were significantly decreased (Figures 3 and 4) .
Compared with normal myocytes, in CHF myocytes, superfusion with BRL (10 Ϫ8 mol/L) caused a more marked decrease in dL/dt max (25.1% versus 13.3%), SA (44.2% versus 29.1%), and dR/dt max (23.6% versus 16.7%) (PϽ0.05) ( Figure  3A and Table) . As displayed in Figure 3B , BRL (10 Ϫ10 to 10 Ϫ7 mol/L) induced dose-dependent inhibition of cell contraction. In the normal myocytes, BRL caused about 14.8%, 25.5%, 31.5%, and 34.2% decreases in SA, respectively. In CHF myocytes, BRL produced significantly greater reductions in SA of 16.6%, 31.5%, 44.2%, and 46.1% (PϽ0.05), respectively. Thus, CHF myocytes exhibited an increased responsiveness to BRL. Of note, BRL of 10 Ϫ8 mol/L decreased SA by 31.5% below control value in normal myocytes. Previously, much higher concentrations of BRL (10 Ϫ7 mol/L) only caused a 26% decrease in peak tension in normal canine ventricular strips, 15 suggesting isolated myocytes may be more sensitive to BRL. As presented in Figure 4 and the Table, these changes in contractile performance were associated with a marked decrease in the peak systolic [Ca 2ϩ ] iT in both normal (17.6%) and CHF (32.8%) myocytes, whereas the BRL-induced decrease in [Ca 2ϩ ] iT was significantly greater in CHF myocytes (32%) than that in normal myocytes (17%) ( Figure 4A ). Compared with normal myocytes, we further found that BRL (10 Ϫ8 mol/L) caused a much greater decrease in I Ca,L in CHF myocytes (32.3% versus 21.6%) ( Figure 4B ).
As displayed in Figure 5 , BRL-induced reductions in SA persisted in normal and CHF myocytes after pretreatment with ␤ 1 -or ␤ 1 -/␤ 2 -AR antagonists. However, pretreatment with bupranolol, which possesses ␤ 3 -AR antagonist properties, completely prevented the action of BRL. Similarly, in the subgroup of 2 animals, ␤ 3 -AR-mediated contractile response also was abolished in the presence of a selective ␤ 3 -AR antagonist (L-748,337). Figure 6 illustrates the contribution of NO ( Figure 6A ) and G i ( Figure 6B ) in BRL-induced contractile action. Pretreat- A, Analog recordings in the field-stimulated myocytes obtained from 1 instrumented dog before and after CHF. In the normal myocytes, BRL (10 Ϫ8 mol/L) inhibited cell contraction and relaxation, with decreases in SA (Ϸ29%), dL/dt max , and dR/dt max . After CHF, BRL caused greater reductions in SA (Ϸ38%), dL/dt max , and dR/dt max , thereby indicating an enhanced cardiac depression. B, Group mean data of concentrationdependent negative inotropic effects of BRL (10 Ϫ10 to 10 Ϫ7 mol/L) in both normal and CHF myocytes. In CHF myocytes, BRL caused more marked reductions in SA, indicating an enhanced cardiac inhibition. ment of myocytes with L-NAME or PTX caused no significant changes in baseline SA, but significantly altered the myocyte response to BRL. As shown in Figure 6A , compared with untreated myocytes, in the presence of L-NAME, BRL-induced decreases in SA were significantly reduced in normal (12.3Ϯ2.9% versus 28.4Ϯ3.0%) and CHF myocytes (15.9Ϯ3.0% versus 42.6Ϯ3.1%) (PϽ0.05). However, in this condition, BRL still significantly decreased SA in normal and CHF myocytes (PϽ0.05). The decreased SA in CHF myocytes remained more marked than that in normal myocytes (15.9% versus 12.3%) (PϽ0.05). In contrast, pretreatment of PTX prevented BRL caused decreases in SA in both normal (Ϫ1.3Ϯ2.1%) and CHF myocytes (Ϫ1.6Ϯ3.0%) ( Figure 6B ).
Discussion
We investigated the alterations in the cardiac ␤ 3 -AR expression and functional effect in an animal model of CHF that mimics many of the functional and neurohormonal changes (especially ␤-AR signaling) of clinical CHF. 1, 3, 13 We found that the functional ␤ 3 -ARs are expressed in normal LV, and their stimulation induces direct inhibition on [Ca 2ϩ ] iT and I Ca,L and produces a negative inotropic action. Importantly, in CHF, ␤ 3 -AR expression is increased. This alteration exacerbates the dysfunctional [Ca 2ϩ ] i homeostasis and [Ca 2ϩ ] i regulation, enhances inhibition of cardiac contraction and relaxation, and may lead to worsening cardiac failure.
Expression and Functional Effect of Cardiac ␤ 3 -AR Before and After CHF
The distribution and functional effect of ␤ 3 -ARs in the heart remains uncertain. Previous experimental studies of cardiac ␤ 3 -ARs in a variety of animals and humans have yielded conflicting results. ␤ 3 -AR stimulation has been reported variably to have a positive, 11 negative, [5] [6] [7] or no inotropic effect 12 on normal LV contractile performance. Both the presence 4,5 and absence 12 of cardiac ␤ 3 -ARs have been documented.
In contrast, we assessed the direct effect of ␤ 3 -AR stimulation with BRL in cardiomyocytes isolated from the LV before and after CHF. These studies removed the effects of extracardiac factors, which may influence contractility. We found that in normal myocytes, BRL produced clear dosedependent depressions of myocyte contraction and relaxation, with significant reductions in SA, dL/dt max , and dR/dt max . BRL-induced inhibitions of cell contraction and relaxation were not modified by pretreatment of myocytes with ␤ 1 -and ␤ 1 -/␤ 2 -AR antagonists, indicating that this effect was not mediated by ␤ 1 -and ␤ 2 -ARs. By contrast, ␤ 3 -AR antagonists completely prevented the BRL-induced contractile action, indicating that the negative inotropic action of BRL is coupled to ␤ 3 -ARs.
We further found that the BRL-induced depression in myocyte contraction was accompanied by significant decreases in [Ca 2ϩ ] iT and I Ca,L . Thus, the BRL-evoked cardiac Figure 5 . Group mean data showing the effects of metoprolol, nadolol, bupranolol, and L-748,337 on BRL-induced inotropic response in normal and CHF myocytes. Pretreatment with these antagonists caused no significant changes in baseline contraction. Only pretreatment of myocytes with bupranolol or L-748,337 prevented BRL-induced effects in both normal and CHF myocytes, whereas persistence of BRL-induced negative inotropic action after pretreatment of myocytes with metoprolol and nadolol indicated that BRL-induced contractile response was not mediated through ␤ 1and ␤ 2 -ARs. Figure 6 . Examples for the effects of NO blockade and G i blockade on BRL-induced contractile responses. Representative superimposed tracings of analog recordings of contractile response to BRL in both normal and CHF myocytes after pretreatment with L-NAME (A) and PTX (B). After pretreatment of myocytes with L-NAME, BRL (10 Ϫ8 mol/L)-induced decreases in SA were greatly reduced. However, the BRL still markedly decreased SA in both normal (Ϸ12%) and CHF myocytes (Ϸ16%), suggesting ␤ 3 -AR activation is not mediated exclusively through the NO pathways. In contrast, pretreatment myocytes with PTX prevented BRL-caused changes in both normal and CHF myocytes, indicating ␤ 3 -AR activation is coupled with G i pathways. This finding may also suggest the existence of multiple pathways for eliciting the negative inotropic effect of ␤ 3 -AR stimulation.
inhibition may be at least partially mediated through [Ca 2ϩ ] i regulation.
We found the presence of cardiac ␤ 3 -ARs, and for the first time, quantified the cardiac ␤ 3 -AR mRNA and ␤ 3 -AR protein levels by using Northern blot and Western blot analyses in normal and CHF canine LV myocytes. These results are consistent with the observations of Gauthier et al, 5 who first demonstrated the presence and functional effect of ␤ 3 -ARs in the human donor heart, but contrary to the findings of Tavernier et al, 12 who reported no functional or biochemical evidence for the presence of ␤ 3 -ARs in the normal dog heart. Their failure to observe functional cardiac ␤ 3 -ARs may have attributed to the use of insensitive measures of ␤ 3 -AR protein with [ 125 I] CYP and inadequate assessment of LV contractility. The present observation is supported by our previously published report that by using pressure-volume analysis in conscious, instrumented dogs, we have clearly demonstrated that BRL directly inhibited LV contraction and relaxation in the normal heart and caused an enhanced inhibition of LV contraction after CHF. These effects persisted at constant heart rate (by atrial pacing) or after autonomic blockade.
A novel finding in the present study is that, in striking contrast with ␤ 1 -ARs, in CHF myocytes, there is an enhanced ␤ 3 -AR stimulation-induced negative inotropic response with an exacerbated negative modulation on [Ca 2ϩ ] i regulation, which is paralleled by an increased ␤ 3 -AR expression.
Consistent with past reports, 3, 13 we found that after pacinginduced CHF, there is a primary defect in the cardiomyocyte force-generating capacity and relaxation process, with impaired [Ca 2ϩ ] i homeostasis. BRL exacerbated the dysfunctional cell contraction and [Ca 2ϩ ] i regulation. BRL caused much greater decreases in [Ca 2ϩ ] iT and I Ca,L in CHF myocytes than in normal myocytes, with resultant decreased SA, dL/dt max , and dR/dt max . In these CHF myocytes, ␤ 3 -AR mRNA and protein levels were significantly increased by 73% and 147%, respectively.
Our finding of the upregulation of both ␤ 3 -AR gene expression and functional response in CHF LV myocytes should be compared with a recent study. Moniotte et al 4 reported a similar upregulation of ␤ 3 -AR expression but blunted negative inotropic response to BRL in human failing myocardium. This discrepancy might result from several confounding factors such as species difference in ␤ 3 -ARs, 15 different severity of CHF, different measurements of contractility, and different tissue (or cell) preparations.
It is likely that the very different observations in ␤ 3 -ARmediated contractile response in CHF between the two studies are mainly owing to the fact that Moniotte et al 4 studied ventricular strips, whereas we examined single LV myocytes. It has been shown that there are different distributions of ␤ 3 -ARs in different cardiac chambers. 19 Thus, in their study, the use of ventricular strips of multiple cells preparation, as well as the clinical use of multiple drugs in the cardiomyopathic patients, may have complicated the accurate assessment of the degree and functional significance of alterations of the LV myocyte response to ␤ 3 -AR stimulation.
In contrast, in our study, BRL-induced contractility changes were compared in isolated single LV myocytes obtained from the same animal before and after advanced CHF. Myocyte cell SA and dL/dt max were used as a measure of contractility, which may provide a more sensitive means of detecting CHF caused changes in myocardial contractile response to ␤ 3 -AR stimulation. Although the ␤ 3 -AR density per myocyte was not measured in the current study, it is possible the significant increase in ␤ 3 -AR gene expression in CHF LV myocytes may be associated with increased ␤ 3 -AR numbers per cell. 2 Thus, the enhanced contractile response to BRL in CHF myocytes may reflect the presence of an increase in the number of ␤ 3 -AR per cell.
Nevertheless, the findings of Moniotte et al 4 and the present study all demonstrated a similar, potentially detrimental functional consequence with ␤ 3 -AR activation in CHF. In CHF, when marked increases in sympathetic tone and cardiac norepinephrine release have rendered the positive inotropic ␤ 1 -AR system relatively unresponsive, the upregulated ␤ 3 -AR pathways would continue to exhibit a negative inotropic effect. This altered balance between opposing inotropic influences of ␤ 1 -ARs and ␤ 3 -ARs in CHF may contribute to progressive cardiac dysfunction in CHF. However, a definitive statement regarding the importance of ␤ 3 -ARs in the pathogenesis of CHF cannot be drawn from the described altered ␤ 3 -ARs in CHF. Whether ␤ 3 -ARs are a contributing cause or merely a result of ventricular dysfunction remains an unresolved question. More insight will be gained from future work demonstrating beneficial actions of ␤ 3 -AR antagonists or adverse actions of ␤ 3 -AR activation in response to endogenous catecholamines, which are currently ongoing.
Potential Mechanism(s) of the Upregulated ␤ 3 -ARs in CHF
In the present investigation, both molecular and functional assessments provide evidence that ␤ 3 -AR is upregulated in the failing canine heart. Although the mechanism for this effect has not yet been elucidated, several lines of evidence suggest that the overexpression of ␤ 3 -ARs in our animal model may be related to the advanced stage of CHF. The prolonged stimulation by catecholamine causes ␤ 1 -AR downregulation and uncoupling. 1 In contrast, the ␤ 3 -ARs are relatively resistant to long-term, agonist-induced desensitization processes 20 and may play an important role in the diminished numbers of ␤ 1 -ARs. Furthermore, norepinephrine, the primary neurotransmitter released by SNS, has relatively high affinity for the ␤ 3 -AR (unlike the ␤ 2 -AR). 21 In addition, G i , implicated in the ␤ 3 -AR signaling, is elevated in failing myocardium. Decreased ␤ 1 -receptor and G s density with increased (50%) G i protein has been reported in pacinginduced CHF. 3 In this investigation, we demonstrated that the altered myocyte inotropic response to BRL is owing to a ␤ 3 -AR stimulation caused by an enhanced negative modulation on [Ca 2ϩ ] i regulation. After CHF, ␤ 3 -AR stimulation exacerbates the dysfunctional [Ca 2ϩ ] i homeostasis, resulting in further reduction in peak systolic [Ca 2ϩ ] iT and I Ca,L . The stimulation of an increased number of ␤ 3 -ARs could have caused the amplified response in CHF myocytes.
The enhanced response to ␤ 3 -AR stimulation in CHF may also be related to increased numbers of ␤ 3 -ARs or an altered signal transduction. Although the intracellular pathway coupling ␤ 3 -AR stimulation is still incompletely characterized, it has been reported that ␤ 3 -AR stimulation decreases cardiac contractility through activation of NO synthase pathway. 6, 10, 15 In CHF, the NO-cGMP signaling may be altered, 22 thereby altering CHF myocyte response to ␤ 3 -AR stimulation. In agreement with previous studies, we found that in the presence of L-NAME, the BRL-induced negative inotropic response was strongly reduced, indicating an involvement of the NO pathway in ␤ 3 -AR-mediated action. However, our present observation indicates that the NO pathway may not be fully responsible for the altered LV myocyte response to BRL because we found that the myocyte response to BRL was only partially inhibited by pretreatment myocytes with NO synthase inhibitor. In the presence of L-NAME, myocyte contractility was still significantly reduced, indicating ␤ 3 -AR activation is not mediated exclusively through the NO pathway. A similar observation has also been made in beating guinea pig hearts. 6 Our study indicates that ␤ 3 -AR-mediated contractile action couples to G i because pretreatment of PTX completely prevented BRL contractile effects in normal and CHF myocytes. This is not consistent with the past report of Gauthier et al. 5 In their study, it was shown that in human ventricular strips treated with PTX, the effect of BRL on contractility was attenuated but was not completely suppressed. This discrepancy is owing to an incomplete blockade of G i by PTX in their study because an inadequate amount of PTX and duration (0.5 g/mL for 2 hours) was used. It has been reported that PTX treatment for 3 to 5 hours at 5 g/mL is required to inactivate human cardiac G i . 16 Therefore, our present study indicated that the enhanced contractile response to ␤ 3 -AR stimulation in CHF myocytes may be coupled to G i through both NO-dependent and NO-independent mechanisms. The activation of G i also has the potential to couple ␤ 3 -ARs to other important signaling pathways such as the MAP kinase. 23 The increase in other neurohormonal activation, such as tumor necrosis factor-␣, endothelin 1, and angiotensin II, may also differentially modulate ␤ 3 -AR expression and function. Clearly, further studies are needed to fully characterize intracellular pathway coupling ␤ 3 -AR stimulation.
Clinical Implications
Our observation and those of others 5,6,10 support the view that in the normal heart, the ␤ 3 -AR pathway may exert a negative counterregulation against excessive positive inotropy. However, increased ␤ 3 -AR expression in CHF myocytes may underlie the progressive nature of functional impairment in CHF. Both the expression and the function of ␤ 3 -ARs are increased after pacing-induced CHF. This finding is a striking contrast with the changes in ␤ 1 -and ␤ 2 -ARs. The upregulated ␤ 3 -ARs in CHF exacerbates the dysfunctional [Ca 2ϩ ] i homeostasis and [Ca 2ϩ ] i regulation and, thus, exhibits a greater inhibition on cardiac contraction and relaxation and might lead to worsening cardiac failure. The implications of these findings are important to our understanding of the pathophysiology of CHF. They may also suggest several novel therapeutic strategies for the treatment of CHF, such as the use of ␤ 3 -AR blockers or G i inhibitors. Our findings also indicate that using ␤ 3 -AR agonists for the treatment of obesity and diabetes 24 may have cardiac side effects, especially in CHF patients.
In conclusion, we found that in dogs with pacing-induced CHF, the gene expression and functional responses of cardiac ␤ 3 -AR are upregulated, which may potentially contribute to the progression of CHF.
